Novartis is a large biopharmaceutical company that develops and sells prescription medicines. Its filings show it lobbies on intellectual property protections for drugs, patent policy, and enforcement; laws affecting drug pricing and access, including pharmacy benefit manager and patient access measures; and trade and tax policies. It reported $160,000 across four filings, most recently in January 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
KARINA LYNCH
The latest disclosures for this client.
DLA PIPER LLP (US)
Q4DLA PIPER LLP (US)
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
DLA PIPER LLP (US)
MARGARET MARTIN
DLA PIPER LLP (US)
MICHAEL SORENSEN
DLA PIPER LLP (US)
RICHARD BURR
DLA PIPER LLP (US)
VINCENT SARUBBI jr
DLA PIPER LLP (US)
mr JAMIE ALEXEI GREGORIAN
DLA PIPER LLP (US)
RACHEL PORTMAN
DLA PIPER LLP (US)
DLA PIPER LLP (US)
Q2DLA PIPER LLP (US)
RR